Inve India ▾

IOL Chemicals and Pharmaceuticals share price & results

IOL Chemicals and Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

World's largest, fully backward-integrated Ibuprofen maker; also produces APIs and specialty chemicals.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue756 ₹ crore+37.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin14.0 %+3.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit64.0 ₹ crore+88.2% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity10.09 %+2.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin1.85 %+3.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)18.51 %+14.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 6 judged targets kept · 13 open · verdicts reflect calls analysed to Q1 FY27.

IOL Chemicals and Pharmaceuticals Limited management guidance track record on Inve: 19 targets tracked across analysed earnings calls (3 achieved, 3 missed, 13 open).

TargetOriginal wordingSaidLatest callVerdict
Capacity UtilizationHoping for that to increase to around 90% in the next two to three quarters.
Call transcript, Q3 FY25 · 14 Feb 2025		Q3 FY25Q1 FY27:Maintained at 80-95%
Call transcript, Q1 FY27 · 13 Aug 2026		Achieved
Export ShareAchieve the export realization or export sale of around 40% to 45% in the next 2 years.
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:Q1 actual 28.5%. New FY27 guidance 25-30%, significantly below original 40-45% target.
Call transcript, Q1 FY27 · 13 Aug 2026		Revised Down
EBITDA MarginWe are expecting more than 15% in the current year.
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q4 FY26:FY26 actual: 12.4%. Original target >15% missed.
Call transcript, Q4 FY26 · 28 May 2026		Missed

Source: Inve Guidance Tracker for IOL Chemicals and Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of IOL Chemicals and Pharmaceuticals Limited's 19 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 16 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹179.36 +6.77% · +₹11.38

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +93.1% 1Y

₹100₹150₹200Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 12 Feb 2026Q4 FY26 — 27 May 2026Q1 FY27 — 13 Aug 2026

1Y: ₹92.9 on 24 Oct 2025 → ₹179.36. High ₹220.22 (7 Oct 2026), low ₹68.21 (17 Mar 2026).

Previous close
₹167.98
Market cap
₹4.9k Cr
52-week range
₹68.21 – ₹220.22
One year
+92.59%
Price to earnings (TTM to Jun 2026)
28.02×
Return on equity (TTM to Jun 2026)
10.09%

Overview

Symbol
NSE:IOLCP
Exchange
NSE
Currency
INR

What IOL Chemicals and Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

IOL Chemicals and Pharmaceuticals manufactures active pharmaceutical ingredients (APIs) and specialty chemicals from its integrated manufacturing complex in Ludhiana, Punjab. It is the world's largest producer of Ibuprofen and the only fully backward-integrated Ibuprofen manufacturer globally, while its non-Ibuprofen API portfolio spans Paracetamol, Metformin, Clopidogrel, Pantoprazole, Fenofibrate and other molecules across therapeutic areas such as anti-diabetic, anti-platelet and anti-hypertensive. Its Specialty Chemicals business produces Ethyl Acetate, Acetic Anhydride, Iso Butyl Benzene and related intermediates, used both captively as inputs for its own API production and sold externally to industries such as flexible packaging, paints, ink, textiles and pesticides. The company serves customers across roughly 80 countries through a mix of regulated and emerging export markets alongside domestic sales.

Segments

  • Pharmaceuticals
  • Specialty Chemicals
Global market position
World's largest producer of Ibuprofen and the only company globally fully backward-integrated for it
Employees
3,000+
Manufacturing footprint
Existing facility spans 180+ acres; expanded with 101 acres purchased on the Chandigarh-Bathinda Highway for a new site
Export reach
Customers across roughly 80 countries
Product portfolio
20 products commercialized, with 9 more in the R&D pipeline
Regulatory filings
14 DMFs with USFDA and 21 CEPs with EDQM
Founded 1986Headquarters 85, Industrial Area 'A', Ludhiana - 141003, Punjab, India Company website

How the price took the results

close before → close after

Q1 FY27
+4.8%
13 Aug
Q4 FY26
−1.8%
28 May
Q3 FY26
−0.9%
12 Feb
Q2 FY26
−0.4%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for IOL Chemicals and Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow IOL Chemicals and Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse IOL Chemicals and Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.